Extract from the above information

This product is a metal complex of platinum, and its action is similar to that of an alkylating agent. Its main target is DNA, and it acts on the cross-links between DNA chains and within the chains to form a DDP-DNA complex, interfering with DNA replication, or binding to nuclear and cytoplasmic proteins. It is a non-specific drug for the cycle.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

This product is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, by preventing uracil and orotic acid from incorporating into RNA, the effect of inhibiting RNA synthesis is achieved. This product is a cell cycle-specific drug that mainly inhibits S-phase cells.

As a folate reductase inhibitor, it mainly inhibits dihydrofolate reductase and prevents dihydrofolate from being reduced to physiologically active tetrahydrofolate, thereby hindering the transfer of one-carbon groups in the biosynthesis of purine nucleotides and pyrimidine nucleotides, resulting in the inhibition of DNA biosynthesis. In addition, this product also has an inhibitory effect on thymic nucleotide synthetase, but its effect on inhibiting RNA and protein synthesis is weaker. This product mainly acts on the S phase of the cell cycle and is a cell cycle-specific drug. It also has a delaying effect on cells in the G1/S phase, but its effect on G1 phase cells is weaker.